Clinical Trial Update: A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABT-493/ABT-530 to Sofosbuvir with Daclatasvir in adults with HCV genotype 3 has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)
• Daclatasvir (daclatasvir)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2017-09-15